Join us for an afternoon discussion around the industry before going on to celebrate the Global Generics & Biosimilars Awards *.

Agenda

Main Discussion
Vision 2030: Growth trajectory & opportunities for Indian Pharma

The promise of specialty drugs, complex generics & 505(b)(2) pathway drugs - leading Indian firms are stepping up efforts in areas like specialty drugs, and complex generics as competition and pricing pressures make plain vanilla generics unattractive.
In-licensing late-stage assets: strategies, challenges, and opportunities. New modalities and partnering advancing the innovation journey - several Indian firms are developing NCEs/NBEs and are also looking at in-licensing and out-licensing assets given the steep learning curve, capability deficit, and investment challenges. There are also plenty of in-licensing/co-marketing efforts on the domestic market and for innovator molecules, with brand rights being assigned to domestic firms.
Biosimilars opportunities & go-to-market strategies: What Indian firms can learn from South Korea - although India has over 95 biosimilars approved on the home market, exports are still largely to other emerging markets and Latin America etc, with some firms making inroads in the US, Europe, and Australia. India has over 200 active biosimilar products estimated to be in the pipeline for 50 plus local firms, yet collectively South Korean firms are still ahead. Perhaps there is lot India can learn from South Korea on manufacturing, partnering and overall industry momentum.
Value deals: Bolt-on acquisitions, brand buys - most Indian firms are conservative when it comes to big ticket M&A and opting for smaller niche deals, particularly in the current volatile situation globally. However recently, there have been some larger transactions and many smaller niche bolt on deals, where much of the action is anticipated, and could provide further opportunities for India.